Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application

Appyea

SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it received approval from the Helsinki Committee to begin its planned clinical trial on the SleepX PRO application. This follows the company’s recent update that it intends to test the SleepX Pro application at a hospital sleep lab. The trial is the first step towards applying for an FDA approval under the first-of-its-kind medical device category for contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep. SleepX Pro, which is designed to diagnose sleep apnea using only a smartphone, requires no physical contact with the subject. Global Smart Sleep Tracking Products Market to Garner a Revenue of USD 11,234.55 Million by 2028 and Grow with a CAGR of 17.50% during 2020-2028; Surge in Concern for Sleep-Related Disorders to Drive the Market Growth, according to Kenneth Research (May 16, 2022). “Poor sleep is associated with the compromised immune system, heart problems, reduce physical and mental performance, mood problems, obesity and many other health problems”, said Neil Kline, Founder & former CEO of the American Sleep Association, and a AppYea Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal in this unique technology is to raise the awareness to the problem and to improve people’s they can live healthier and more fulfilling lives.” “SleepX PRO makes for a unique, quick and friendly diagnosis tool that will prevent subjects from having to spend nights at sleep labs while saving the healthcare system and insurance companies hundreds of millions of dollars”, said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chair at AppYea. “We plan to make our diagnosis solution highly accessible so people get tested easily. SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details Asaf Porat +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

May 31, 2022 08:30 AM Eastern Daylight Time

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring one for multiple sclerosis and developing a potential cure for diabetes, has received a patent from the Japan Patent Office for AstroRx ® for the treatment of ALS and drug screening. The patent also protects AstroRx® for the treatment of multiple sclerosis. AstroRx® is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells. The cells are intended to support the central nervous system (brain and spinal cord), impaired by neurological diseases such as ALS and multiple sclerosis, which disrupt voluntary muscle movement. In a first of its kind Phase I/IIa clinical trial, healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal cord fluid of 10 ALS patients in a standard lumbar puncture. Data showed that AstroRx® delayed the progression of ALS by three months in ALSFRS-R measurement in both tested AstroRx doses. In the next clinical trial of AstroRx®, the plan is to test if this three-month effect can be prolonged with repeated doses every three months of the off-shelf product of AstroRx®. Kadimastem remains on track to submit an IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. Kadimastem CEO Asaf Shiloni said, “The Japanese patent strengthens our intellectual property and gives our cell therapy products top priority in the very important and large Southeast Asian region of the world. In addition, we are exploring the possibilities of business partnerships with the pharmaceutical industry in Japan, both for AstroRx® for ALS and IsletRx for diabetes.” Kadimastem Chief Scientist Professor Michel Revel said, "Japan is a prominent territory. This patent protects a significant and highly unique technology and provides a solid IP advantage for Kadimastem." The Japanese market is one of the most significant for stem cell-derived cell therapies. Japan has strategic importance in this field, as it is at the forefront of the international community supporting innovation and the development of products in the field of cell therapy. In November 2014, the Japanese Parliament approved a special law 1 to facilitate clinical trials in the field of cellular medicine, with the aim of expediting approvals of intracellular therapies and quickly bringing them to market. Japan has more than 12,000 ALS patients and this number continues to increase as the population ages. The treatment of these patients is currently estimated at an annual $ 1 billion 2. [1] Azuma K. Regulatory Landscape of Regenerative Medicine in Japan. Curr Stem Cell Reports. 2015; 1: 118–128. doi:10.1007/s40778-015-0012-6 [2] Doi et al., J Epidemiol. 2014; 24(6): 494–499. doi: 10.2188/jea.JE20140059. Prevalence of ~0.01 of Japanese population of 125 M (https://worldpopulationreview.com/countries/japan-population) =12,500 About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

May 30, 2022 09:10 AM Eastern Daylight Time

Image

Hong Kong Baptist University-led research identifies new regulatory mechanism of satiety and therapeutic target for obesity

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 30 May 2022 - A research team led by Hong Kong Baptist University (HKBU) has found that a proteolytic enzyme called membrane-type 1 matrix metalloproteinase ( MT1-MMP) plays an important role in the regulatory mechanism of fullness, or satiety, and it could serve as a promising potential drug target for the management of obesity. Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (left), and Professor Bian Zhaoxiang, Director of the Clinical Division of the School of Chinese Medicine and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU (right), identified a proteolytic enzyme called MT1-MMP which could serve as a promising potential drug target for the management of obesity. The research findings were published in the internationally-renowned scientific journal Nature Metabolism. The study has also been featured as a research highlight in multiple high-impact journals, including Nature Reviews Endocrinology, Nature Metabolism and Science Signaling. Half of Hong Kong’s population obese or overweight Being overweight, especially to the extent of obesity, exposes people to a higher risk of life-threatening diseases such as cardiovascular diseases, diabetes, and cancer. According to the Population Health Survey conducted in 2014/15 by the Department of Health, about 30% of people in Hong Kong aged 15 to 84 were obese, and another 20% were overweight. The most effective way to tackle obesity is to reduce food consumption, but obese people often encounter difficulties in regulating their dietary habits as they lose their sense of satiety. Identifying a factor that specifically controls body weight, and investigating how it regulates our sense of satiety, is crucial for the development of therapeutic approaches for obesity. Identification of new regulator of satiety signals A research team led by Dr Xavier Wong Hoi-leong, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (SCM), and Professor Bian Zhaoxiang, Director of the Clinical Division of SCM and Tsang Shiu Tim Endowed Chair of Chinese Medicine Clinical Studies at HKBU, identified a proteolytic enzyme called MT1-MMP which regulates the mechanism of issuing satiety signals in the human brain. Growth and differentiation factor 15 (GDF15) is a hormone that sends out satiety signals by binding with the neuron receptor in the hindbrain called GDNF-family receptor α-like (GFRAL). Mediation of GFRAL can therefore affect the ability of GDF15 to send satiety signals, and thus help regulate food intake. From this starting point, the research team conducted a series of experiments to investigate the mediation effects of MT1-MMP on GFRAL. Depletion of MT1-MMP reduces obesity The research team generated an obesity mouse model by feeding a fat-rich diet to a group of transgenic mice with a depletion of MT1-MMP in their satiety neurons, as well as a control group of ordinary mice. After 16 weeks, the mice with depleted MT1-MMP ate 10% less food, gained 50% less weight, and exhibited reduced glucose and plasma insulin levels compared to the control group. The results show that depletion of MT1-MMP protects mice from obesity induced by a high-fat diet. Following analysis with western blots, a widely used analytical technique that can detect specific proteins, the research team also found that the obese mice displayed an increased activity of MT1-MMP in the Area Postrema and Nucleus of the Solitary Tract, the brain regions involved in appetite and weight regulation. The finding suggests that increased MT1-MMP activity in the brain of obese mice could be a risk factor causing sustained weight gain. To understand the mechanism by which MT1-MMP suppresses GDF15 satiety signalling, the research team conducted a series of molecular biology experiments involving animal models and cell culture. The results show that in cells with active MT1-MMP, a significant reduction of GFRAL and thus GDF15 signalling were observed. It could be explained by MT1-MMP clipping GFRAL from the surface of the brain neurons, which blocks GDF15 from binding to GFRAL and thus reduces the number of satiety signals. This in turn keeps the neurons from transmitting the satiety signals sent by GDF15. MT1-MMP as a therapeutic target for obesity The researchers also explored the therapeutic potential of targeting MT1-MMP for obesity management, in particular through pharmacological inhibition of its activity in vivo. With the application of a specific neutralising antibody that inhibits MT1-MMP, significant improvements in metabolic parameters including food intake, glucose tolerance and body weight in obese mice were observed. The results suggest that MT1-MMP is a potential therapeutic target that could be used in the development of innovative drug treatments for obesity. Dr Wong said: “The research findings have established the role played by MT1-MMP in regulating satiety, and they have provided preliminary indications that the proteolytic enzyme is a promising target for the treatment of obesity. Pharmacological inhibition of MT1-MMP could be a viable strategy for the development of effective pharmacotherapy for the treatment of obesity.” Apart from researchers from HKBU, the research team included scientists from The University of Hong Kong, The Chinese University of Hong Kong, the University of Texas Health Science Center at Houston, and the University of Helsinki. #HongKongBaptistUniversity #HKBU Contact Details Christina Wu from the Communication and Public Relations Office +852 3411 7828 christinawu@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

May 30, 2022 04:26 AM Eastern Daylight Time

Image

Nutritional Supplement Manufacturer Nutramax Laboratories Exceeds Industry Standards for Quality

Nutramax Laboratories

For 30 years, Nutramax Laboratories has diligently adhered to industry-leading quality controls and manufacturing standards. This commitment to quality has been affirmed by Nutramax’s utilization of third-party, independent auditing and certification programs. Nutramax Laboratories recently completed a rigorous conformance assessment for the GMP certification program administered by Underwriters' Laboratories (UL), the global safety science leader in auditing and certification. The annual certification covers a full GMP audit criterion based on 21 CFR Part 111, Good Manufacturing Practices for dietary supplements. This marks the third year of the UL Certificate of Conformance program; the successful audits featuring three different auditors are a testament to the quality systems, facilities, equipment, processes, and the superb employees of Nutramax. Nutramax’s quality procedures include rigorous testing and inspection at every stage of the manufacturing process and go above and beyond the standards governing the industry. “ We choose to go above and beyond what is required because it is the only way to be certain that the products released for sale meet a defined set of the quality standards that our customers deserve,” says Godwin Omorogieva, Vice President of Quality at Nutramax. As the #1 veterinarian recommended supplement company, Nutramax Laboratories Veterinary Sciences has earned the trust of its valued customers by providing them with innovative products that are backed by science and held to the highest standard. “Supporting the health of pets is our priority,” says President and CEO, Todd Henderson, DVM. “In our ongoing pursuit of excellence for the next 30 years, and beyond, we pledge our loyalty to customers with a continued commitment to uphold the highest standards in quality control, manufacturing, and research.” Nutramax Laboratories Veterinary Sciences’ products are manufactured in state-of-the-art facilities in accordance with Good Manufacturing Practices (GMPs) and a strict set of Standard Operating Procedures (SOPs). It has long been their tradition to back each supplement with scientific studies that support their safety and efficacy, ensuring that customers can be confident that what the packaging states, can be trusted. For more information on the Nutramax Laboratories quality standard, visit nutramaxlabs.com/our-quality or speak to a dedicated Customer Service team member at (888) 886-6442. Nutramax Laboratories Veterinary Sciences, Inc. develops, and markets supplements backed by research for companion animals to help support their quality of life. Small animal products include Cosequin®, the #1 Veterinarian Recommended Retail Joint Health Supplement Brand*,**; Dasuquin®, the #1 veterinarian-recommended joint health supplement brand*; the #1 veterinarian-recommended liver support brand Denamarin®***; and products supporting urinary tract health, digestive health, and skin/coat health plus overall wellness. To learn more, call (888) 886-6442 or visit nutramaxlabs.com. *Source: Among retail brands. Survey conducted among small animal veterinarians who recommend oral joint health supplements. **Source: Among veterinary brands. Survey conducted among small animal veterinarians who recommended oral joint health supplements. ***Source: Survey conducted among small animal veterinarians who recommended liver support brands. Contact Details Erika Dyer +1 703-906-6368 erika@curleycompany.com Company Website https://www.nutramaxlabs.com/

May 26, 2022 09:48 AM Eastern Daylight Time

Legal & General Capital makes first U.S. investment, with seed capital for $4Bn platform to fund major life-science and technology assets across multiple regional U.S. markets

Legal & General

Legal & General Capital (LGC) today announced that it has formed a 50:50 partnership with U.S.-based real estate developer Ancora to create a real estate platform dedicated to driving life science, research and technology growth across the U.S. The deal will see Legal & General Capital investing an initial $500 million of seed capital to form a new company, Ancora L&G, LLC. Operating under the name Ancora, the business’ geographic focus will sit predominantly within emerging regional markets in the U.S. where early mover advantages are available. The new venture builds on the successful track record of Ancora’s team and the investing record of LGC in the UK, including over $5 billion currently committed to science and technology development projects at Oxford and Manchester universities. Ancora will be capitalized by LGC to deliver $4 billion (£3.2bn) of existing pipeline and planned acquisition and development activity over the next five years. To support future growth, LGC is seeking third party co-investment partners to accelerate scaling the portfolio. As with other LGC investments, LGC aims to finance longer term cashflows and use them to back Legal & General’s annuity business, providing better value for policyholders and greater options for investors. LGC has a strong track record of establishing and scaling up innovative businesses and has led the way in driving science and technology growth through its Bruntwood SciTech partnership, the UK’s leading developer of innovation districts. Bruntwood SciTech has quickly expanded over 11 UK locations, a model LGC will look to replicate across the U.S. Observed Laura Mason, CEO of Legal & General Capital, “Through our partnership with Ancora, we will be able to leverage Legal & General’s significant experience in the science and technology sector in a new international market with strong growth potential. Remaining committed to investing in the real economy to create a better society over the long term, for the first time we take this ethos to an international level beyond the UK’s town and city centers.” Legal & General Group currently manages over $1.8 trillion of assets globally and is increasing its presence in the U.S. for both equity and debt vehicles. Marking LGC’s first venture into the U.S., this partnership with Ancora forms an important part of its major growth strategy to deliver internationalization and attract third party capital. Notes Sir Nigel Wilson, Chief Executive of Legal & General Group, “While the U.S. is the world’s largest commercial real estate market, the lab real estate market in particular is one of the smallest sectors among other commercial U.S. asset classes. This lack of scale creates high barriers to entry for investors and has made it particularly challenging for tenants to grow due to scarcity of supply. LGC’s ability to access this opportunity via Ancora will set it apart from other sources of institutional capital seeking to participate in the market.” Ancora is a privately owned real estate firm based in Durham, North Carolina with team members in Baltimore, Boston, Chicago, Indianapolis, New York, and Washington, DC. The firm acquires and develops real estate to serve high-growth science, technology, and innovation tenants in partnership with and proximate to leading U.S. anchor institutions. Core to Ancora’s program-first approach is undertaking development activity in direct partnership with anchor institutions such as universities, academic medical centers, government, and research institutes with whom they have strong and long-lasting relationships. This unique approach in the U.S. market resonates with the way LGC has looked to deploy capital through leveraging strategic partnerships to invest in socially and economically useful developments around the globe. Ancora L&G, LLC will be led by Josh Parker as Chief Executive Officer, alongside John Philipchuck as Chief Investment Officer, Jeff Kingsbury as Chief Connectivity Officer and Nicole Morrill as Chief Real Estate Officer. LGIMA’s Kristina St.Charles will move across from LGIMA as General Counsel and Legal and General’s Sujee Rajah, FCA ICAEW, will move across to Ancora L&G, LLC as its new Chief Finance Officer. Having qualified with Deloitte’s Assurance department, he has held various senior roles within the Legal & General Group, most recently as Group Investor Relations director. As part of its growth ambitions, Ancora will work closely with Legal & General Investment Management (LGIM) and its global client base as LGIM continues to expand its Real Assets expertise into the US market. Josh Parker, Chairman and CEO of Ancora L&G, noted, "Ancora's ability to deliver Real Estate for What’s Next that serves the needs of our anchor institution partners will be accelerated by this new venture with Legal & General. We can meet any anchor institution requirement with an experienced team and strong capital base aligned with the timelines and aspirations of universities, academic medical centers, government, and research centers.” He added, “Our team is excited to leverage the deep capital base of Legal & General and third-party clients to offer new investment options for our university partners, and we are eager to deliver activated districts of research and innovation that will enhance local economies across the United States. " At its Capital Markets Event at the end of last year, LGC set out plans to generate up to £600 million in profit from alternative assets by 2025, growing its alternative asset portfolio to £5 billion and generating returns of around 10 to 12 percent per annum, across its key focus areas of housing, small and medium-enterprise finance, specialist commercial real estate and clean energy. It is now looking at each of these sectors as part of its U.S. expansion. Laura Mason observed, “We see a strong alignment between our business strategy and Ancora’s strategy, with a commitment to investing long term in high-growth sectors and leveraging strategic partnerships to attract third party co-investment. As we look to grow our business at scale, we have major growth plans both in the UK and internationally, and this is just the start.” Notes to editors About Legal & General Capital Legal & General Capital (LGC) is Legal & General Group’s alternative asset platform, creating assets for Legal & General Retirement and third-party clients in order to achieve improved risk-adjusted returns for our shareholders. LGC has built its market leading capabilities in a range of alternative assets, delivering depth of resource, track record and intellectual property. Investing in the real economy and creating alternative assets that deliver a tangible societal impact, its purpose is to invest society’s capital for society’s benefit. LGC’s investments have been vertically integrated and include residential property, specialist commercial real estate, clean energy, alternative credit, and venture capital. As LGC’s capability to create alternative assets continues to grow, it will not only continue to grow its balance sheet of alternative assets but also create alternative assets for third party investors. Many of these investors have the same aims, namely to create assets to back pensions with an improved yield or to create assets with strong growth prospects but with low correlation to equities. L&G has invested around £30 billion (about $37 million) in levelling-up regional UK economies, including through major regeneration projects in Cardiff, Newcastle and Salford. Legal & General recently made a commitment to enable all new homes across its portfolio to operate at net zero carbon emissions by 2030, including Legal & General Modular Homes, CALA Group, Legal & General Affordable Homes, Build to Rent and Later Living. The company has strong track record of investing in technology and life sciences with its Bruntwood SciTech venture, the UK’s leading developer of innovation districts, creating the specialist environments and innovation ecosystems for science and technology businesses to form, scale and grow. A 50:50 joint venture between Bruntwood and Legal & General, Bruntwood SciTech provides high quality office and laboratory space and tailored business support, offering unrivaled access to finance, talent and markets, an extensive clinical, academic and public partner network, and a sector-specialist community of over 500 companies. Bruntwood SciTech has unique experience in creating and developing strategic partnerships with UK regional cities, universities, and NHS Trusts to drive economic growth through investment in science and technology infrastructure. Valued at over £600m ($750.4m), Bruntwood SciTech has now expanded over 11 UK locations with a portfolio of over 2.4m sqft including: - Alderley Park in Cheshire, the UK’s latest single-site science park and home to Cancer Research UK, Catapult and Evotec - £162.9m ($203.6m) - Melbourn Science Park in Cambridge - £52.8m ($66m) - Platform in Leeds - £44.8m ($56m) - Innovation Birmingham - £29.2m ($36.5m) - Manchester Science Park - £73.9m ($92.3m) - Citylabs 1.0 & 2.0 part of the Manchester University NHS Foundation Trust (MFT) campus - £78.5m ($98.1m) - Circle Square Manchester - £205.7m ($257.1m) It has a further development pipeline of 5m sqft, which includes $260m Birmingham Health Innovation Campus, $1.8bn ID Manchester and $37m Glasgow’s Met Tower. Ancora Founded in 2019 by Josh Parker, with co-founders John Philipchuck and Jeff Kingsbury, Ancora is a privately owned real estate firm based in Durham, North Carolina with team members in Baltimore, Boston, Chicago, Indianapolis, New York, and Washington, DC. The firm acquires and develops real estate to serve high-growth science, technology, and innovation tenants in partnership with and proximate to leading U.S. anchor institutions. Core to Ancora’s program-first approach is to undertake development activity in direct partnership with anchor institutions such as universities, academic medical centers, government, and research institutes with whom they have strong and long-lasting relationships. About Legal & General Group Established in 1836, Legal & General is one of the UK’s leading financial services groups and a major global investor, with international businesses in the U.S., Europe, Middle East and Asia. With over $1.4 trillion in total assets under management, Legal & General is the UK’s largest investment manager for corporate pension schemes and a UK market leader in pension risk transfer, life insurance, workplace pensions and retirement income. Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.legalandgeneralgroup.com/

May 25, 2022 08:00 AM Eastern Daylight Time

VinFuture Prize 2022 officially announces commencement of the pre-screening round

Vingroup

HANOI, VIETNAM - Media OutReach – 19 May 2022 - On May 18 th, 2022 – The commencement of VinFuture Pre-Screening Round has been officially announced. Honoring the theme of “Reshaping and Reviving”, the VinFuture Prize has received a total of 970 nominations, submited by prestigious scientists and institutions from more than 70 countries in six continents for its second award season. Under this year’s theme, nominations are centered around important research works and inventions that can help revive the post-pandemic world by solving humanity’s most pressing challenges related to health and the food supply, the environment and sustainable energy, as well as the application of technology in all aspects of life. Currently leading in number of nominators is Asia with 34.6% of the total accepted nominators, followed by the Americas with 29.8%, Europe with 16.2%, and Oceania with 7%. Notably this year, Africa has 12.4% of the nominators, six times higher than its share in 2021. In terms of quality, 584 out of 2618 nominators of the VinFuture Prize’s second season are individual nominators from the top 2% of most-cited researchers in the world, and 37.1% are from the world’s top 500 universities and research institutions, such as Harvard University, Stanford University, Yale University (U.S.A), University of Oxford (U.K.), Karolinska Institute (Sweden), Swiss Federal Institute of Technology, National University of Singapore, Tsinghua University (China), University of the Witwatersrand, Johannesburg (South Africa), Cairo University (Egypt), and many other leading universities and institutions globally. The VinFuture Pre-Screening round consists of a rigorous evaluation process based on the highest international standards in order to ensure scientific integrity, fairness, and transparency. The VinFuture Pre-Screening Committee will assess the nominations according to a set of core criteria, which includes the degree of scientific or technological advancement, the level of impact on people’s lives, as well as the project’s scale and sustainability. Dr. Lê Thái Hà, Managing Director of the VinFuture Prize, shared, “ Witnessing the consequences of two years of the COVID-19 pandemic, VinFuture recognizes its role in contributing to, and promoting, the global process of post-pandemic revival, aiming ultimately for sustainable development. With the theme of “Reshaping & Reviving”, the VinFuture Prize 2022 has gathered leading scientists from a variety of science and technology fields from across the world to increase the number of multi-dimensional perspectives in the nomination evaluation process. From this, we hope to find scientific solutions to the world’s pressing problems, and to simultaneously inspire and disseminate the great values that science and technology can bring in different sectors to new countries and territories, particularly in vulnerable areas. ” With the official commencement of the Pre-Screening round, the 2022 VinFuture Prize has announced three additional scientists to join its Scientific Councils this season. Professor Dan Kammen from the University of California, Berkeley (U.S.A), the former Science Envoy for the U.S. State Department, one of the world’s leading experts in the field of energy, will be officially joining the VinFuture Prize Council from 2022. The two other new professors joining the VinFuture Pre-Screening Council for the second season include Professor Quarraisha Abdool Karim – The 2016 L’Oréal-UNESCO for Women in Science Laureate, one of the Inaugural VinFuture Prize Laureates, and Professor Ermias Kebreab - the Director of the University of California, Davis World Food Center. Sharing his thoughts about his new role, Professor Dan Kammen said, “ I was especially impressed by VinFuture’s realistic message, as well as the mission of science and technology that has been disseminated through VinFuture’s humanitarian angle. I have high expectations for not only the quality, but also the applicability of the scientific nominations to real life. As a scientist who is dedicated to science for humanity, being able to participate in evaluating the nominations and choosing the scientific inventions and innovations to be the next Prize winners is a meaningful and enjoyable mission. ” The 2022 VinFuture Pre-Screening round takes place from May 18 th to late September, 2022 and aims to enable the Council to meticulously evaluate the most impactful and award-worthy works to proceed to the final round. VinFuture Prize Council: - Professor Sir Richard Henry Friend, FRS – University of Cambridge, UK, Millennium Technology Laureate in Physics 2010. - Professor Gérard Albert Mourou – École Polytechnique Palaiseau, France, Nobel Laureate in Physics 2018. - Professor Sir Konstantin (Kostya) S. Novoselov, FRS – University of Manchester, UK and National University of Singapore, Nobel Laureate in Physics 2010. - Professor Michael Eugene Porter – Harvard Business School, USA, creator of the theory "Competitive Advantage of Nations". - Professor Leslie Gabriel Valiant, FRS – Harvard University, USA, A.M. Turing Laureate 2010. - Dr. Padmanabhan Anandan – AI Matters Advisors LLC, USA. - Professor Jennifer Tour Chayes – University of California, Berkeley, USA. - Professor Pascale Cossart – Pasteur Institute of Paris, France. - Professor Van-Chi Dang – Ludwig Institute for Cancer Research, USA. - Dr. Xuedong David Huang – Microsoft, USA. - Professor Dan Kammen – University of California, Berkeley, USA. - Professor Ha-Van Vu – Yale University, USA and VinBigdata Institute, Vingroup, Vietnam. VinFuture Pre-Screening Committee: - Professor Thuc-Quyen Nguyen - University of California, Santa Barbara, USA. - Professor Albert P. Pisano - University of California, San Diego, USA. - Professor Mônica Alonso Cotta – Institute of Physics “Gleb Wataghin”, University of Campinas, Brazil. - Professor Ngoc-Minh Do - University of Illinois Urbana-Champaign, USA and VinUniversity, Vietnam. - Mr. Akihisa Kakimoto - Mitsubishi Chemical Corporation, Japan. - Prof. Quarraisha Abdool Karim - CAPRISA Center for the AIDS Programme of Research in South Africa - Professor Ermias Kebreab - University of California, Davis, USA. - Professor Duc-Thu Nguyen - Rutgers University, USA. - Professor Alta Schutte - University of New South Wales and The George Institute for Global Health, Australia. - Professor Molly Shoichet - University of Toronto, Canada. - Professor Vivian Yam – The University of Hong Kong, Hong Kong. About the VinFuture Foundation: The VinFuture Foundation, established on December 20th, 2020 on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation initiated by Mr. Phạm Nhật Vượng, and his wife, Madam Phạm Thu Hương. The mission and vision of the Foundation is to create meaningful changes in the everyday lives of millions of people in the world. The core activity of the Foundation is awarding the annual VinFuture Prize to technological innovations that have already contributed or have the potential to contribute to the betterment of life for millions of human beings globally. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. Contact Details Vingroup Media Contact v.nammh@vingroup.net

May 19, 2022 09:30 AM Eastern Daylight Time

Image

Green Cubes Technology Expands Executive Team

Green Cubes Technology

Green Cubes Technology, a leader in electrification and clean, connected, cost-effective power solutions, today announced four significant executive appointments to its leadership team - Ken Gregory as Vice President of Supply Chain and Procurement, Alan Forster as Vice President of Sales for Americas, Rita Faunce as Vice President of Sales Operations and Customer Experience, and Rocio Castellanos as International Controller. These executives join Ken Johnson, who was appointed Chief Operating Officer (COO) last year. The team will provide leadership to sales, supply chain, operations, manufacturing, and customer support functions for continued growth within Motive (including Ground Support & Materials Handling), Stationary (Telecom & Data Center), and Mobile (Industrial Automation) Power market segments. “We’re very pleased to add so many talented professionals to Green Cubes’ executive team,” said Keith Washington, CEO of Green Cubes Technology. “This reflects the rapid growth of the company, and the leadership that each of these individuals bring to the company will help us continue to lead the charge to electrification.” Mr. Gregory has a history of success with enterprise operations and transformation, customer experience, supply chain and channel/alliance sales across enterprise and consumer Information Technology, Education and Learning organizations. He has driven sustainable cultural and digital transformations in highly matrixed organizations resulting in increased revenue, enhanced customer confidence, organizational capability, and employee engagement. He brings over 25 years of core supply chain experience gained at IBM supporting its enterprise computer hardware segments. Mr. Gregory’s most recent experiences were at Pearson, a global leader in learning and education where he oversaw customer service and digital operations transformation. Mr. Forster is responsible for managing and accelerating Green Cubes’ pipeline and revenue growth while developing its channel and sales enablement programs. In his recent role as Sales Director for the company’s Telecom and Data Center business unit (operating as Unipower), he helped rebuild sales and channel relationships, managed consistent quarterly growth, and increased sales channel coverage during the global pandemic. By working diligently with the Unipower team, he doubled bookings and revenue during a global supply chain and transportation slow down. Ms. Faunce directs Green Cubes’ sales operations teams globally, drives its customer experience strategy, and will facilitate ownership of customer experience excellence. She has vast experience managing global teams in sales operations, customer service, and customer satisfaction with success in delivering customer facing programs that foster a spirit of transparency, continuous improvement, and mutual accountability in customer relationships. Ms. Faunce will implement continuous improvement plans, leverage customer insights and data, and work across multiple departments to ensure team members and leadership are aware of and dedicated to the goals of continuously improving the customer experience. Ms. Castellanos joins Green Cubes as a key member of the global finance and accounting team. She is responsible for the internal and external financial reporting of all Green Cubes affiliated entities outside the U.S. In her role, she will support the entities in financial reporting topics and bridge the information to the U.S. headquarters. She will focus on continuous improvement of processes and deliverables to enhance financial performance visibility across the entities, as well as act as a strategic business advisor for International Operations. Ms. Castellanos brings over 20 years of experience and has worked for various companies including PwC, Swiss Life and Daniel Swarovski Corp. The expansion of Green Cubes’ executive team follows the company’s announcement last year that it added a second 36,000 square foot domestic facility in Kokomo, Indiana, and expanded its product lines for Motive and Stationary Power to support accelerated growth in Material Handling and Telecom markets. The Kokomo facility is currently increasing its manufacturing throughput and is expecting a 150% increase in Motive Power shipments in 2022, relative to 2021. Additionally, Green Cubes previously announced that it established two new facilities in Europe and a Technology Center in Zurich, Switzerland. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With a global footprint across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information at https://greencubes.com/. Contact Details Ray Young +1 512-633-6855 ray@razorsharppr.com Company Website https://greencubestech.com/

May 19, 2022 09:00 AM Eastern Daylight Time

G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues

G Medical Innovations Holdings

Irvine, CA – May 18, 2022 – G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company”), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022. While the Company is still working on finalizing most of the revenue figures for the first quarter, the previously reported purchase orders received by the Company from McDade Products, LLC for 6 million co-branded LiveNow COVID-19 PCR Test Collection Kits (approximately $20 million in orders) have not materialized into revenues due to a slowdown of the pandemic in the US during the first quarter. Approximately $6 million of invoices have been submitted for payment, out of which $0.7 million has been received and another batch of claims of approximately $1 million is to be filed for payment. Further, the proposed budget for COVID-19 tests which has not yet been approved by the U.S. Congress creates further uncertainty as to revenue the Company expected to receive and recognize from sales of such tests in its testing centers. The Company plans to announce the final revenues numbers for the first quarter of 2022 as part of its financial results release for the first six months of 2022. The Biden administration has announced that it expects another outbreak of the pandemic as early as this fall with new variants and expects about 100 million patients, which we believe will increase the need for tests. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward looking statement in this press release when it is providing an update regarding its forecast for first quarter 2022 revenue in connection with the previously reported purchase orders, uncertainty of additional government funding for COVID-19 tests and the belief in an increased need for COVID-19 testing in the future. Because such actions deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of the Company could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 29, 2022, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

May 18, 2022 04:05 PM Eastern Daylight Time

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). Kadimastem remains on track to submit IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services and Development Ltd. Hadasit is the technology transfer arm of Hadassah Medical Center. It is well known for its partnerships with international companies and research institutions, and its success with groundbreaking medical developments that fill unmet market needs. Under the terms of the agreement, Kadimastem’s astrocyte cells, which comprise AstroRx®, the company’s flagship product for ALS, will be tested for their therapeutic potential for MS using a unique animal model in Professor Tamir Ben-Hur’s laboratory at Hadassah Medical Center. Professor Ben-Hur is the Director of Brain Medicine at Hadassah Ein Kerem Medical Center and a pioneer and opinion leader in the field of clinical research in multiple sclerosis. If successful, the goal is to thereafter plan and conduct a clinical trial of AstroRx® for MS. "We are very excited about the expansion of the range of neurological diseases that astrocyte cells (AstroRx®) could be used to treat. The pre-clinical study that will be conducted at Professor Ben-Hur's laboratory is extraordinary. It’s a first-of-its-kind in the world to treat multiple sclerosis, " said Professor Michel Revel, Israel Prize Winner, Kadimastem Founder and Chief Scientist, and famous for his groundbreaking research that led to the development of the blockbuster drug Rabif for multiple sclerosis. Kadimastem CEO Asaf Shiloni said, “Expanding our R&D activity by conducting the ALS and the MS research in parallel enables us to provide maximum value for patients and investors alike. We are working diligently to move the ALS clinical program ahead. We also hope that AstroRx® will be the answer for the millions of MS patients for whom the usual method of treatment is ineffective. The use of AstroRx® cells, with their various mechanisms of action, may lead to an innovative regenerative treatment for the disease." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 a.shiloni@kadimastem.com Company Website https://www.kadimastem.com/

May 18, 2022 07:00 AM Eastern Daylight Time

Image

1 ... 166 167 168 169 170 ... 226

Why News Direct

For Public Relations For Investor Relations Testimonials

About us Features News Hub

Resources

Press Blog

Why News Direct For Public Relations For Investor Relations Testimonials

What We Offer Collaborative Content Studio Advanced News Release Capability Standalone Multimedia Distribution Industry-Leading Security Unsurpassed Global Reach Actionable Analytics Synergistic PR Solutions

Pricing About us News Hub

Resources Blog Press